Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

AML × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 23 Myelodysplastic Syndromes 6 Myeloproliferative Disorders 5 Glioma 4 Cholangiocarcinoma 4 Leukemia 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Recurrence 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasm Metastasis 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Hematologic Neoplasms 2 Ependymoma 2 Biliary Tract Neoplasms 2 Xanthogranuloma, Juvenile 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Unknown Primary 1 Neoplasm, Residual 1 Lymphoma, Follicular 1 IDH1-Mutated Malignancies 1 IDH1 Mutation Myeloid Neoplasms 1

Interventions

ivosidenib 1 Magnesium 1 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06717958 2025-07-02

PIVOT

Technische Universität Dresden

Phase 2 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡